39 results
8-K
EX-99.1
CUE
Cue Biopharma Inc
9 May 24
Cue Biopharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
4:01pm
-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995
8-K
EX-10.1
CUE
Cue Biopharma Inc
15 Nov 22
Cue Biopharma Announces $30 Million Private Investment in Public Equity (PIPE) Financing
4:30pm
to give notice shall materially adversely affect the indemnifying party in the defense of any such claim or litigation. It is understood … or litigation. No indemnified party will, except with the consent of the indemnifying party, which consent shall not be unreasonably withheld
8-K
EX-10.2
CUE
Cue Biopharma Inc
15 Nov 22
Cue Biopharma Announces $30 Million Private Investment in Public Equity (PIPE) Financing
4:30pm
that such failure to give notice shall materially adversely affect the indemnifying party in the defense of any such claim or litigation. It is understood … or litigation.
(d) Contribution. If for any reason the indemnification provided for in the preceding paragraphs (a) and (b) is unavailable
8-K
EX-10.1
dy0d0
30 Mar 22
Entry into a Material Definitive Agreement
4:10pm
8-K
EX-99.1
fdljeypoxtr25t x5s
15 Nov 21
Regulation FD Disclosure
7:57am
8-K
EX-1.1
f4uy nn3vqdc
1 Oct 21
Entry into a Material Definitive Agreement
5:01pm
8-K
EX-10.1
zdl11hty 4v
24 Aug 20
Entry into a Material Definitive Agreement
4:21pm
8-K
EX-1.1
qwc9a
22 Jun 20
Entry into a Material Definitive Agreement
5:26pm